Belgian biotech UCB has made its second acquisition of the year, agreeing a front-loaded takeover of US biotech Candid ...

In 2022, obesity contributed just 1% of the projected value of pharma industry pipeline, as calculated by Deloitte. Now, its ...

After failing to muster sufficient support for an IPO last year, autoimmune and inflammatory disease specialist Odyssey ...

mRNA specialist BioNTech has chalked up an important win in its cancer pipeline, showing efficacy with its BNT111 vaccine candidate in a phase 2 trial in advanced melanoma. The study is looking at the ...

Pfizer and Arvinas are poised to bring the third oral selective oestrogen receptor degrader (SERD) to market in the US, after ...

Over the past decade, neurodegenerative research and development has responsibly answered a foundational question: can we ...

In its first meeting for months, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted against AstraZeneca's oral ...

The first volunteers in a large-scale trial of Moderna's mRNA-based vaccine against bird flu – long considered to be a ...

As a tech lover, I soak it all in and leave inspired about what’s next. This was the case recently when I attended Google ...

In another major setback for abortion care in the US, a US court has issued an order restricting the distribution of ...

Avalyn Pharma has priced its initial public offering (IPO) on the Nasdaq, hoping to raise an upscaled $300 million for its ...